NRx Pharmaceuticals to Discuss Neuroplasticity and Psychedelic Treatments at BTIG Virtual Biotechnology Conference

NRx Pharmaceuticals (NASDAQ: NRXP) has announced that its CEO and Chairman, Prof. Jonathan Javitt, MD, MPH, will engage in a fireside chat at the BTIG Virtual Biotechnology Conference on July 29–30, 2025. The session, set for 8:00 a.m. EDT on July 30, will include Prof. Samuel Wilkinson, MD, from Yale School of Medicine, and BTIG Research Analyst Dr. Thomas Shrader. The discussion will center on neuroplasticity's role in treating central nervous system (CNS) disorders, with a particular emphasis on ketamine and other neuroplastic and psychedelic drugs for conditions such as depression, suicidality, and PTSD.

NRx Pharmaceuticals is at the forefront of developing therapeutics based on its NMDA platform, targeting CNS disorders like suicidal bipolar depression, chronic pain, and PTSD. The company's NRX-101, an FDA-designated investigational Breakthrough Therapy, is being developed for suicidal treatment-resistant bipolar depression and chronic pain, with plans to file for Accelerated Approval. Additionally, NRX-101 shows promise as a non-opioid treatment for chronic pain and a remedy for complicated UTI.

The company is also advancing a New Drug Application for NRX-100 (IV ketamine) for suicidal depression, leveraging data from clinical trials and French health authorities. NRx has received Fast Track Designation from the US FDA for ketamine (NRX-100) as part of a protocol to treat acute suicidality.

This participation highlights NRx Pharmaceuticals' commitment to pioneering treatments in the psychedelic and cannabis industries, potentially offering new hope for patients with CNS disorders. The discussion at the BTIG conference underscores the growing interest and investment in psychedelic therapies as viable treatments for mental health conditions, marking a significant moment for the industry and patients alike.